Some future antiresorptive drugs that are not yet improved by US food and drug administration (FDA), include calcitriol, genistein, other bisphosphonates (etidronate, pamidronate, and tiludronate), PTH (1-84), sodium fluoride, strontium ranelate, and also tibolone.
Osteoporosis future or investigational therapies
Osteoporosis primary prevention
Osteoporosis secondary prevention
Osteoporosis medical therapy
Osteoporosis cost-effectiveness of therapy
Hypoparathyroidism future or investigational therapies
Vitamin D deficiency medical therapy
Osteoarthritis medical therapy